1
                                                                    Exhibit 99.1

WARNER CHILCOTT TO ISSUE $200 MILLION SENIOR NOTES

DUBLIN, Ireland and ROCKAWAY, N.J., Feb. 14/PRNewswire/--Warner Chilcott, plc
(Nasdaq; WCRX - news) today announced that its wholly owned subsidiary, Warner
Chilcott, Inc., has entered into an agreement for the issuance of $200 million
of Senior Notes due 2008. This 144A transaction was managed by Credit Suisse
First Boston, with CIBC World Markets and S.G. Cowen and Company participating
as co-managers. The closing is scheduled for February 15, 2000.

Interest on the Notes will accrue at the rate of 12.625% per annum and will be
payable semiannually commencing on August 15, 2000. The Notes will mature on
February 15, 2008 but are redeemable by the Company after February 15, 2004.
Payments under the Notes will be guaranteed by Warner Chilcott, plc. Proceeds
of the Offering will be used primarily to fund the previously announced
acquisition of three branded pharmaceutical products from Bristol-Myers Squibb
Company.

Warner Chilcott is a developer and marketer of prescription pharmaceutical
products in the United States, primarily focused on the women's health
therapeutic category. Through its national sales force of over 260
representatives, Warner Chilcott markets branded pharmaceutical products
directly to physician specialists across the country, particularly
obstetrician/gynecologists and urologists. The Company's principal offices are
in Dublin, Ireland and Rockaway, New Jersey.

Note:

Statements made in this press release include forward-looking statements made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements, including those relating to financial expectations for
the fiscal year 2000 and beyond, involve certain risks and uncertainties that
could cause actual results to differ materially from those in the forward
looking statements, including, but not limited to, the company's dependence on
key products, risks associated with product development and manufacturing, the
uncertainty of future financial results and fluctuations in operating results,
dependence on the companies' acquisition strategy, new product introductions and
other risks described from time to time in the companies' SEC filings. These
forward-looking statements represent the judgment of the company, as of the date
of this release, and the company disclaims any intent or obligation to update
these forward-looking statements. Information on other significant potential
risks and uncertainties not discussed herein may be found in the Company's
filings with the Securities and Exchange Commission including its Form 10K for
the year ended December 31, 1998 and Form 10Q for the quarter ended September
30, 1999.